Mono Pharmacare Limited (NSE: MONOPHARMA.NS) Stock Competitors & Peer Comparison

Mono Pharmacare Limited (NSE: MONOPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MONOPHARMA.NS stands at 149.3M. In comparison, ENTERO.NS has a market cap of 62B. Regarding current trading prices, MONOPHARMA.NS is priced at ₹8.45 on the NSE, while ENTERO.NS trades at ₹1,423.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MONOPHARMA.NS currently has a P/E ratio of 4.83, whereas ENTERO.NS's P/E ratio is 46.91. In terms of profitability, MONOPHARMA.NS's ROE is N/A, compared to ENTERO.NS's ROE of +0.07%. Regarding short-term risk, MONOPHARMA.NS is less volatile compared to ENTERO.NS. This indicates lower risk in terms of short-term price fluctuations for MONOPHARMA.NS.Check ENTERO.NS's competition here

Mono Pharmacare Limited (NSE: MONOPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MONOPHARMA.NS stands at 149.3M. In comparison, EVERESTO.BO has a market cap of 2.9B. Regarding current trading prices, MONOPHARMA.NS is priced at ₹8.45 on the NSE, while EVERESTO.BO trades at ₹297.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MONOPHARMA.NS currently has a P/E ratio of 4.83, whereas EVERESTO.BO's P/E ratio is 52.25. In terms of profitability, MONOPHARMA.NS's ROE is N/A, compared to EVERESTO.BO's ROE of +0.07%. Regarding short-term risk, MONOPHARMA.NS is less volatile compared to EVERESTO.BO. This indicates lower risk in terms of short-term price fluctuations for MONOPHARMA.NS.Check EVERESTO.BO's competition here

Mono Pharmacare Limited (NSE: MONOPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MONOPHARMA.NS stands at 149.3M. In comparison, QMSMEDI.NS has a market cap of 2.9B. Regarding current trading prices, MONOPHARMA.NS is priced at ₹8.45 on the NSE, while QMSMEDI.NS trades at ₹148.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MONOPHARMA.NS currently has a P/E ratio of 4.83, whereas QMSMEDI.NS's P/E ratio is 21.23. In terms of profitability, MONOPHARMA.NS's ROE is N/A, compared to QMSMEDI.NS's ROE of N/A. Regarding short-term risk, MONOPHARMA.NS is less volatile compared to QMSMEDI.NS. This indicates lower risk in terms of short-term price fluctuations for MONOPHARMA.NS.Check QMSMEDI.NS's competition here

Mono Pharmacare Limited (NSE: MONOPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MONOPHARMA.NS stands at 149.3M. In comparison, ACHYUT.BO has a market cap of 1.7B. Regarding current trading prices, MONOPHARMA.NS is priced at ₹8.45 on the NSE, while ACHYUT.BO trades at ₹7.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MONOPHARMA.NS currently has a P/E ratio of 4.83, whereas ACHYUT.BO's P/E ratio is 700.00. In terms of profitability, MONOPHARMA.NS's ROE is N/A, compared to ACHYUT.BO's ROE of +0.01%. Regarding short-term risk, MONOPHARMA.NS is less volatile compared to ACHYUT.BO. This indicates lower risk in terms of short-term price fluctuations for MONOPHARMA.NS.Check ACHYUT.BO's competition here

Mono Pharmacare Limited (NSE: MONOPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MONOPHARMA.NS stands at 149.3M. In comparison, RAMAVISION.BO has a market cap of 1.7B. Regarding current trading prices, MONOPHARMA.NS is priced at ₹8.45 on the NSE, while RAMAVISION.BO trades at ₹161.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MONOPHARMA.NS currently has a P/E ratio of 4.83, whereas RAMAVISION.BO's P/E ratio is 166.32. In terms of profitability, MONOPHARMA.NS's ROE is N/A, compared to RAMAVISION.BO's ROE of +0.21%. Regarding short-term risk, MONOPHARMA.NS is less volatile compared to RAMAVISION.BO. This indicates lower risk in terms of short-term price fluctuations for MONOPHARMA.NS.Check RAMAVISION.BO's competition here

Mono Pharmacare Limited (NSE: MONOPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MONOPHARMA.NS stands at 149.3M. In comparison, BALAXI.NS has a market cap of 1.2B. Regarding current trading prices, MONOPHARMA.NS is priced at ₹8.45 on the NSE, while BALAXI.NS trades at ₹22.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MONOPHARMA.NS currently has a P/E ratio of 4.83, whereas BALAXI.NS's P/E ratio is -4.23. In terms of profitability, MONOPHARMA.NS's ROE is N/A, compared to BALAXI.NS's ROE of +0.01%. Regarding short-term risk, MONOPHARMA.NS is less volatile compared to BALAXI.NS. This indicates lower risk in terms of short-term price fluctuations for MONOPHARMA.NS.Check BALAXI.NS's competition here

Mono Pharmacare Limited (NSE: MONOPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MONOPHARMA.NS stands at 149.3M. In comparison, BIJHANS.BO has a market cap of 642.2M. Regarding current trading prices, MONOPHARMA.NS is priced at ₹8.45 on the NSE, while BIJHANS.BO trades at ₹85.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MONOPHARMA.NS currently has a P/E ratio of 4.83, whereas BIJHANS.BO's P/E ratio is 570.80. In terms of profitability, MONOPHARMA.NS's ROE is N/A, compared to BIJHANS.BO's ROE of N/A. Regarding short-term risk, MONOPHARMA.NS is more volatile compared to BIJHANS.BO. This indicates higher risk in terms of short-term price fluctuations for MONOPHARMA.NS.Check BIJHANS.BO's competition here

Mono Pharmacare Limited (NSE: MONOPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MONOPHARMA.NS stands at 149.3M. In comparison, VIVOBIOT.BO has a market cap of 428.5M. Regarding current trading prices, MONOPHARMA.NS is priced at ₹8.45 on the NSE, while VIVOBIOT.BO trades at ₹19.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MONOPHARMA.NS currently has a P/E ratio of 4.83, whereas VIVOBIOT.BO's P/E ratio is -23.55. In terms of profitability, MONOPHARMA.NS's ROE is N/A, compared to VIVOBIOT.BO's ROE of -0.03%. Regarding short-term risk, MONOPHARMA.NS is less volatile compared to VIVOBIOT.BO. This indicates lower risk in terms of short-term price fluctuations for MONOPHARMA.NS.Check VIVOBIOT.BO's competition here

Mono Pharmacare Limited (NSE: MONOPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MONOPHARMA.NS stands at 149.3M. In comparison, RAJNISH.BO has a market cap of 396M. Regarding current trading prices, MONOPHARMA.NS is priced at ₹8.45 on the NSE, while RAJNISH.BO trades at ₹0.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MONOPHARMA.NS currently has a P/E ratio of 4.83, whereas RAJNISH.BO's P/E ratio is -6.50. In terms of profitability, MONOPHARMA.NS's ROE is N/A, compared to RAJNISH.BO's ROE of -0.05%. Regarding short-term risk, MONOPHARMA.NS is less volatile compared to RAJNISH.BO. This indicates lower risk in terms of short-term price fluctuations for MONOPHARMA.NS.Check RAJNISH.BO's competition here

Mono Pharmacare Limited (NSE: MONOPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MONOPHARMA.NS stands at 149.3M. In comparison, CBPL.BO has a market cap of 376.5M. Regarding current trading prices, MONOPHARMA.NS is priced at ₹8.45 on the NSE, while CBPL.BO trades at ₹49.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MONOPHARMA.NS currently has a P/E ratio of 4.83, whereas CBPL.BO's P/E ratio is 12.35. In terms of profitability, MONOPHARMA.NS's ROE is N/A, compared to CBPL.BO's ROE of +0.10%. Regarding short-term risk, MONOPHARMA.NS is less volatile compared to CBPL.BO. This indicates lower risk in terms of short-term price fluctuations for MONOPHARMA.NS.Check CBPL.BO's competition here

Mono Pharmacare Limited (NSE: MONOPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MONOPHARMA.NS stands at 149.3M. In comparison, NEXUSSURGL.BO has a market cap of 106.6M. Regarding current trading prices, MONOPHARMA.NS is priced at ₹8.45 on the NSE, while NEXUSSURGL.BO trades at ₹19.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MONOPHARMA.NS currently has a P/E ratio of 4.83, whereas NEXUSSURGL.BO's P/E ratio is 228.86. In terms of profitability, MONOPHARMA.NS's ROE is N/A, compared to NEXUSSURGL.BO's ROE of +0.56%. Regarding short-term risk, MONOPHARMA.NS is less volatile compared to NEXUSSURGL.BO. This indicates lower risk in terms of short-term price fluctuations for MONOPHARMA.NS.Check NEXUSSURGL.BO's competition here

Mono Pharmacare Limited (NSE: MONOPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MONOPHARMA.NS stands at 149.3M. In comparison, NATURO.BO has a market cap of 51.5M. Regarding current trading prices, MONOPHARMA.NS is priced at ₹8.45 on the NSE, while NATURO.BO trades at ₹2.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MONOPHARMA.NS currently has a P/E ratio of 4.83, whereas NATURO.BO's P/E ratio is -5.93. In terms of profitability, MONOPHARMA.NS's ROE is N/A, compared to NATURO.BO's ROE of -0.02%. Regarding short-term risk, MONOPHARMA.NS is less volatile compared to NATURO.BO. This indicates lower risk in terms of short-term price fluctuations for MONOPHARMA.NS.Check NATURO.BO's competition here

Mono Pharmacare Limited (NSE: MONOPHARMA.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MONOPHARMA.NS stands at 149.3M. In comparison, EVOQ.BO has a market cap of 42.6M. Regarding current trading prices, MONOPHARMA.NS is priced at ₹8.45 on the NSE, while EVOQ.BO trades at ₹1.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MONOPHARMA.NS currently has a P/E ratio of 4.83, whereas EVOQ.BO's P/E ratio is -17.10. In terms of profitability, MONOPHARMA.NS's ROE is N/A, compared to EVOQ.BO's ROE of -0.01%. Regarding short-term risk, MONOPHARMA.NS is more volatile compared to EVOQ.BO. This indicates higher risk in terms of short-term price fluctuations for MONOPHARMA.NS.Check EVOQ.BO's competition here